The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio

For Immediate Releases

Chicago, IL – December 26, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie Inc. ABBV, The Coca-Cola Co. KO, Chevron Corp. CVX, ImmuCell Corp. ICCC and Precipio, Inc. PRPO.

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for AbbVie, Coca-Cola and Chevron

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. The Coca-Cola Co. and Chevron Corp., as well as two micro-cap stocks ImmuCell Corp. and Precipio, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Xmas Eve Jobless Claims: Still Accommodating

Today's Featured Research Reports

AbbVie’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+31.6% vs. +19.5%). The company has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications. These should support top-line growth in the next few years. Its oncology and neuroscience drugs are also contributing to top-line growth.

AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE. It has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth.

However, the company faces several headwinds like Humira LOE impact, increasing competitive pressure on Imbruvica and continued macro headwinds for Aesthetics.

(You can read the full research report on AbbVie here >>>)

Shares of Coca-Cola have outperformed the Zacks Beverages - Soft drinks industry over the past year (+14.5% vs. +10.5%). The company’s performance reflects the strength of its strategy and the resilience of its global portfolio. The company’s momentum has been fueled by solid organic revenue growth, effective pricing actions, and continued gains in global value share across the non-alcoholic RTD category.

KO’s ongoing focus on innovation, digital transformation, and marketing excellence further sharpens its competitive edge, with breakthrough product launches and culturally resonant campaigns elevating brand relevance. Margin expansion driven by productivity gains, easing inflation and disciplined revenue growth management reinforces its financial durability.

However, KO continues to face meaningful pressures, with soft volumes across key regions, persistent currency headwinds, and a rising tax burden weighing on profitability.

(You can read the full research report on Coca-Cola here >>>)

Chevron’s shares have gained +9.5% over the past year against the Zacks Oil and Gas - Integrated - International industry’s gain of +16%. The company’s acquisition of Hess has meaningfully reshaped its growth outlook, adding high-quality assets in Guyana, the Bakken and the Gulf of Mexico. These additions strengthen its resource base, diversify its upstream portfolio, and reinforce long-term free cash flow potential.

The Permian Basin remains the company’s crown jewel, driving consistent organic growth and industry-leading returns through its low-cost, high-margin profile. Meanwhile, new deepwater projects such as Ballymore and Whale are fueling output momentum in the Gulf.

However, lower crude realizations, regulatory headwinds in California, and higher valuation multiples temper optimism. With its strong balance sheet and disciplined capital approach, Chevron is best viewed as a Neutral for now.

(You can read the full research report on Chevron here >>>)

Shares of ImmuCell have outperformed the Zacks Medical - Products industry over the past year (+26.3% vs. +1%). This microcap company with a market capitalization of $52.65 million offers a compelling investment case, driven by product leadership, operational recovery and improving financial strength. Its First Defense franchise remains the category leader in calf scours prevention, with Tri-Shield comprising 70% of volume and a 48% calf-level market share.

New functional feed products add incremental growth optionality. Operational bottlenecks have been resolved, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million (up 16% YoY) and the gross margin rebounding to 43%. Profitability has improved meaningfully, with $1.8 million in net income YTD versus a prior-year loss and TTM EBITDA of $5.8 million.

A strengthened balance sheet, ample liquidity and refinanced debt enhance financial flexibility. Meanwhile, Re-Tain’s disciplined regulatory path and growing international exposure provide longer-term upside without near-term capital strain.

(You can read the full research report on ImmuCell here >>>)

Precipio’s shares have outperformed the Zacks Medical Info Systems industry over the past year (+361.2% vs. -1.3%). This microcap company with a market capitalization of $40.80 million is moving toward self-funded growth, led by its Pathology Services division, which delivers steady organic growth, rising margins and strong operating leverage. Excess capacity and a lean cost base allow incremental volume to generate high-margin cash flow, supporting R&D and financial stability.

The Products division is scaling, with solid growth but near-term margin pressure from planned infrastructure and staffing investments that should ease as volume rises. Results show improving profitability, positive cash flow and reduced losses, supporting the dual-division strategy. Capital discipline has improved, reducing reliance on equity funding.

However, key risks include liquidity constraints, customer and receivables concentration, LDT regulatory uncertainty and distributor execution. Valuation reflects caution, with upside if cash-flow durability is proven.

(You can read the full research report on Precipio here >>>)

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]                                     

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research